Request A Call Back
What is Sunitix 50mg?
Sunitix 50mg is a product of Beacon Pharmaceuticals Ltd - Bangladesh, Used for kidney cancer, pancreatic neuroendocrine tumor, and gastrointestinal soft tissue cancer. In addition, some other studies, the drug can also respond well when used in some patients with meningococcal cancer, leukemia and other solid tumors, although these indications are not yet approved.
Drug information Sunitix 50mg
- Drug class: Anti-cancer drugs
- Active ingredient: Sunitinib.
- Content: 50mg.
- Dosage form: Hard capsule.
- Packaging: Box of 28 tablets.
- Origin: Bangladesh.
Pharmacological properties and mechanism of action
- Sunitinib inhibits the receptor tyrosine kinases complex (RTKs) involved in tumor growth, angiogenesis, and cancer progression.
- Sunitinib inhibits platelet derived maturation factor receptors, vascular endothelial maturation factor receptors, cell stem factor receptors, Fms-like tyrosine kinase-3, and Fms type 1 receptors. Cluster-stimulating factor and neurotrophic factor receptor derived from astrocytes.
- Sunitinib inhibits the phosphorylation of complex receptors RTKs in RTK target-expressing tumor ligands in vivo and has been shown to inhibit tumor growth or tumor remission and/ or inhibited metastasis in some experimental models of cancer.
- Absorption: After oral administration, maximum plasma concentrations (Cmax) are usually observed within 6-12 hours (Tmax). Food does not affect the bioavailability of sunitinib.
- Distribution: In vitro, sunitinib is 95% bound, and the active metabolite is 90% bound to plasma proteins and is independent of concentration in the range of 100-4000 nanograms/mL.
- Metabolism: Sunitinib is mainly metabolised by cytochrome P450 enzymes, CYP3A4 to the major active metabolite, then further metabolised by CYP3A4. .
- Elimination: Excreted mainly through feces (61%); renally only 16% of the dose for sunitinib itself and its metabolites remains.
- Sunitix 25mg